Safety and Efficacy Evaluation of LX111 Gene Therapy in DME Patients — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Safety and Efficacy Evaluation of LX111 Gene Therapy in DME Patients — Stella

Home/Diabetic Macular Edema (DME)/

View on ClinicalTrials.gov

Recruiting

Back to Diabetic Macular Edema (DME) trials

Early Phase 1 — Very small initial tests in humans, typically just a few people, to make sure the treatment is safe enough to study further.

Trial locations(2 sites)

China

Shanghai General Hospital, Shanghai

Zhongshan Hospital, Shanghai

Key details

Phase

Very early testing

Sponsor

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Collaborators

Innostellar Biotherapeutics Co.,Ltd

Enrollment target

~32 participants

Started

March 2026

Primary completion

September 2027

Age range

18 Years and older

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.